Risk adjusted net present value: What is the current valuation of Spur Therapeutics’s FLT-201?
FLT-201 is a gene therapy commercialized by Spur Therapeutics, with a leading Phase II program in Gaucher Disease Type I.…
FLT-201 is a gene therapy commercialized by Spur Therapeutics, with a leading Phase II program in Gaucher Disease Type I.…
PF-07264660 is a monoclonal antibody commercialized by Pfizer, with a leading Phase II program in Atopic Dermatitis (Atopic Eczema). According…
Influenza (quadrivalent) vaccine is a mrna vaccine commercialized by Pfizer, with a leading Phase III program in Influenzavirus B Infections.…
CTX-112 is a gene-modified cell therapy commercialized by CRISPR Therapeutics, with a leading Phase II program in Marginal Zone B-cell…
Suzetrigine is a small molecule commercialized by Vertex Pharmaceuticals, with a leading Phase III program in Post-Operative Pain. According to…
RL-007 is a small molecule commercialized by Atai Life Sciences, with a leading Phase II program in Diabetic Neuropathic Pain.…
Rezatapopt is a small molecule commercialized by PMV Pharmaceuticals, with a leading Phase II program in Endometrial Cancer. According to…
Atirmociclib is a small molecule commercialized by Pfizer, with a leading Phase III program in Human Epidermal Growth Factor Receptor…
Idrebormilast is a small molecule commercialized by Pfizer, with a leading Phase II program in Rosacea. According to Globaldata, it…
Osivelotor is a small molecule commercialized by Pfizer, with a leading Phase III program in Sickle Cell Disease. According to…